AU2001278755A1 - Injections - Google Patents

Injections

Info

Publication number
AU2001278755A1
AU2001278755A1 AU2001278755A AU7875501A AU2001278755A1 AU 2001278755 A1 AU2001278755 A1 AU 2001278755A1 AU 2001278755 A AU2001278755 A AU 2001278755A AU 7875501 A AU7875501 A AU 7875501A AU 2001278755 A1 AU2001278755 A1 AU 2001278755A1
Authority
AU
Australia
Prior art keywords
injections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278755A
Inventor
Naoki Asakawa
Takayuki Doen
Masao Nagao
Nobuyuki Takechi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001278755A1 publication Critical patent/AU2001278755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001278755A 2000-08-18 2001-08-17 Injections Abandoned AU2001278755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-248468 2000-08-18
JP2000248468 2000-08-18
PCT/JP2001/007075 WO2002015908A1 (en) 2000-08-18 2001-08-17 Injections

Publications (1)

Publication Number Publication Date
AU2001278755A1 true AU2001278755A1 (en) 2002-03-04

Family

ID=18738370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278755A Abandoned AU2001278755A1 (en) 2000-08-18 2001-08-17 Injections

Country Status (5)

Country Link
US (1) US7396841B2 (en)
EP (1) EP1310252A4 (en)
AU (1) AU2001278755A1 (en)
CA (1) CA2419067C (en)
WO (1) WO2002015908A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
WO2003101452A1 (en) * 2002-06-03 2003-12-11 Aurobindo Pharma Ltd. Process for the preparation of highly pure rabeprazole sodium salt
DK2526996T3 (en) * 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulation for intracutaneous injection
EP1713476B1 (en) * 2003-11-05 2010-05-05 Lyka Labs Limited Process for the preparation of benzimidazoles
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
WO2006106903A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
BRPI0617987A2 (en) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composition, pharmaceutical composition, effervescent dosage form, multiple unit oral oral pharmaceutical composition, extended release pharmaceutical dosage form, enteric coated pharmaceutical dosage form, stable pharmaceutical dosage form for oral administration to mammalian subjects, method for treating diseases acid-related diseases by inhibiting gastric acid secretion, method for treating a bacterial infection caused or caused by helicobacter pylori, process for preparing a compound of formula 3, process for preparing a compound of formula 5, use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion, use of a compound of formula 1 for the preparation of a medicament for treating a bacterial infection caused or caused by helicobacter pyl or use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
SG11201401921YA (en) 2011-10-31 2014-05-29 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CN106573106B (en) 2014-08-06 2021-06-22 Xeris药物公司 Syringe, kit and method for intradermal and/or subcutaneous injection of a paste
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
CN105017352B (en) * 2015-07-02 2017-08-22 广东药科大学 A kind of indole alkaloid glucoside and its application
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
CN109381435B (en) * 2017-08-02 2021-11-19 南京斯帕克医药科技有限公司 Dexlansoprazole freeze-dried powder injection, preparation method and application thereof
CN113069421A (en) * 2021-03-29 2021-07-06 海南锦瑞制药有限公司 Lansoprazole for injection
CN113679680B (en) * 2021-09-28 2022-12-30 海南葫芦娃药业集团股份有限公司 Lansoprazole freeze-dried powder for injection and preparation method thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
DK399389A (en) 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd INJECTABLE SOLUTIONS
DK0382489T3 (en) 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoclonal Anti-Human Papillomavirus Antibody, Hybridoma Cell Producing This, and Method of Preparation thereof
JPH0720865B2 (en) 1989-02-10 1995-03-08 武田薬品工業株式会社 Antibacterial agent
NZ254237A (en) * 1992-07-28 1995-12-21 Astra Ab Injectable solution of a 2-[(2-pyridyl)methylsulphinyl]-benzimidazole or a salt thereof; an injection kit
JP3954115B2 (en) 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ Injection and injection kit
TW280770B (en) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
JPH07157440A (en) 1993-10-15 1995-06-20 Takeda Chem Ind Ltd Composition for medicine
JP3859742B2 (en) 1995-04-14 2006-12-20 武田薬品工業株式会社 Liver disease treatment
FR2740686B1 (en) 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510643C2 (en) * 1997-06-27 1999-06-14 Astra Ab Thermodynamically stable omeprazole sodium form B
ES2268800T3 (en) * 1997-10-14 2007-03-16 Eisai Co., Ltd. PHARMACEUTICAL FORMULATION THAT INCLUDES GLYCIN AS A STABILIZER
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
SE9903831D0 (en) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DE60123800T2 (en) 2000-08-04 2007-10-11 Takeda Pharmaceutical Co. Ltd. SALTS OF BENZIMIDAZOLE DERIVATIVES AND THEIR USE

Also Published As

Publication number Publication date
WO2002015908A1 (en) 2002-02-28
EP1310252A4 (en) 2009-06-10
US20030191157A1 (en) 2003-10-09
US7396841B2 (en) 2008-07-08
CA2419067C (en) 2008-12-23
CA2419067A1 (en) 2002-02-28
EP1310252A1 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
AU6419701A (en) Electropancreatography
AU2001262847A1 (en) Language-understanding
AU2001292739A1 (en) 1-oxorapamycins
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001278755A1 (en) Injections
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001274548A1 (en) Syringe
AU2001220246A1 (en) Neckphone
AU2002211620A1 (en) Autoanastomosis
AU2001258349A1 (en) Bisacylguanidine
AU2001296577A1 (en) Chlorophyllases
AU2001279754A1 (en) Indoloquinazolinones
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2002211128A1 (en) Step-bike
AU2001290931A1 (en) Ski-snowboard
AU2001258924A1 (en) Microsatellite-aflp
AU2001293852A1 (en) Sulfonylguanidine
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001281921A1 (en) Bdellosomes
AU2001291876A1 (en) Triazolo-epothilones
AU2002214354A1 (en) Neck-phone
AU2001260192A1 (en) Glycinamides
AU2001284173A1 (en) Calycins
AU2001262711A1 (en) Cytoprotectors